Axonics receives health canada approval for fourth-generation rechargeable sacral neuromodulation system

Irvine, calif.--( business wire )--axonics, inc. (nasdaq: axnx), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that health canada has approved the company's fourth-generation rechargeable sacral neuromodulation system.
AXNX Ratings Summary
AXNX Quant Ranking